MiR-221 Promotes Capan-2 Pancreatic Ductal Adenocarcinoma Cells Proliferation by Targeting PTEN-Akt

Cellular Physiology and Biochemistry

Volumn 38, Issue 6, 2016, Pages 2366-2374

  Yang, Wenzhuo ^a   Yang, Yanning ^a   Xia, Lu ^a   Yang, Yuefeng ^a,b   Wang, Fei ^a   Song, Meiyi ^a   Chen, Xiaoyu ^a   Liu, Jingqi ^a   Song, Yang ^a   Zhao, Yingying ^a   Yang, Changqing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG HOSPITAL   (China)

Author keywords

Akt; Capan 2; MiR 221; Pancreatic ductal adenocarcinoma; PTEN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MICRORNA 221; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; MICRORNA; MIRN221 MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

ADENOCARCINOMA CELL LINE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; ADENOCARCINOMA; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREATIC DUCT; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ADENOCARCINOMA; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC DUCTS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84969964521     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000445589     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. Song B, Zheng K, Ma H, Liu A, Jing W, Shao C, Li G, Jin G: MiR-429 determines poor outcome and inhibits pancreatic ductal adenocarcinoma growth by targeting TBK1. Cell Physiol Biochem 2015;35:1846-56.
5. Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
6. Bartel DP: Micrornas: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
7. Song B, Zhang C, Li G, Jin G, Liu C: MiR-940 inhibited pancreatic ductal adenocarcinoma growth by targeting MyD88. Cell Physiol Biochem 2015,35:1167-77.
8. Ambros V: Micrornas: Tiny regulators with great potential. Cell 2001;107:823-826.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: Microrna expression profiles classify human cancers. Nature 2005;435:834-838.
10. Song W, Li Q, Wang L: Modulation of FoxO1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem 2015;35:184-90.
11. Callegari E, Gramantieri L, Domenicali M, D'Abundo L, Sabbioni S, Negrini M: Micrornas in liver cancer: A model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ 2015;22:46-57.
12. Croce CM, Calin GA: Mirnas, cancer, and stem cell division. Cell 2005;122:6-7.
13. Phuah NH, Nagoor NH: Regulation of micrornas by natural agents: New strategies in cancer therapies. Biomed Res Int 2014;2014:804510.
14. Chen WX, Hu Q, Qiu MT, Zhong SL, Xu JJ, Tang JH, Zhao JH: Mir-221/222: Promising biomarkers for breast cancer. Tumour Biol 2013;34:1361-1370.
15. Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N, Xie Y: Association of serum microrna expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. Plos One 2014;9:e109347.
16. Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H: Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res 2014;6:391-401.
17. Yau TO, Wu CW, Dong Y, Tang CM, Ng SS, Chan FK, Sung JJ, Yu J: Microrna-221 and microrna-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br J Cancer 2014;111:1765-1771.
18. Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE: Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate 2014;74:1655-1662.
19. Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H, Otsuji E: Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 2013;108:361-369.
20. Yamashita R, Sato M, Kakumu T, Hase T, Yogo N, Maruyama E, Sekido Y, Kondo M, Hasegawa Y: Growth inhibitory effects of miR-221 and miR-222 in non-small cell lung cancer cells. Cancer Med 2015;4:551-564.
21. Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ: Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010;39:425-435.
22. Basu A, Alder H, Khiyami A, Leahy P, Croce CM, Haldar S: Microrna-375 and microrna-221: Potential noncoding rnas associated with antiproliferative activity of benzyl isothiocyanate in pancreatic cancer. Genes Cancer 2011;2:108-119.
23. Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, Philip PA, Li Y: Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of pten, p27(kip1), p57(kip2), and puma. Am J Cancer Res 2013;3:465-477.
24. Su A, He S, Tian B, Hu W, Zhang Z: Microrna-221 mediates the effects of pdgf-bb on migration, proliferation, and the epithelial-mesenchymal transition in pancreatic cancer cells. Plos One 2013;8:e71309.
25. Jo H, Mondal S, Tan D, Nagata E, Takizawa S, Sharma AK, Hou Q, Shanmugasundaram K, Prasad A, Tung JK, Tejeda AO, Man H, Rigby AC, Luo HR: Small molecule-induced cytosolic activation of protein kinase akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A 2012;109:10581-10586.
26. Semba S, Itoh N, Ito M, Harada M, Yamakawa M: The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (ly294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells. Clin Cancer Res 2002;8: 1957-1963.
27. Bei Y, Song Y, Wang F, Dimitrova-Shumkovska J, Xiang Y, Zhao Y, Liu J, Xiao J, Yang C: Mir-382 targeting pten-akt axis promotes liver regeneration. Oncotarget 2016;7:1584-1597.
28. Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, Li L, Qin J, Chen Y, Cho WC, Pestell RG, Liang L, Yu Z: Mir-221/222 promotes s-phase entry and cellular migration in control of basal-like breast cancer. Molecules 2014;19:7122-7137.
29. Sun X, Liu B, Zhao XD, Wang LY, Ji WY: Microrna-221 accelerates the proliferation of laryngeal cancer cell line hep-2 by suppressing apaf-1. Oncol Rep 2015;33:1221-1226.
30. Yang F, Wang W, Zhou C, Xi W, Yuan L, Chen X, Li Y, Yang A, Zhang J, Wang T: Mir-221/222 promote human glioma cell invasion and angiogenesis by targeting timp2. Tumour Biol 2015;36:3763-3773.
31. Yang X, Yang Y, Gan R, Zhao L, Li W, Zhou H, Wang X, Lu J, Meng QH: Down-regulation of miR-221 and miR-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of sirt1. Plos One 2014;9:e98833.
32. Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z, Chun-Sheng K: Microrna-221 and microrna-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting pten. BMC cancer 2010;10:367.
33. Carnero A, Paramio JM: The pten/pi3k/akt pathway in vivo, cancer mouse models. Front Oncol 2014;4:252.
34. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N: Akt inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer cell 2011;19:58-71.
35. Hers I, Vincent EE, Tavare JM: Akt signalling in health and disease. Cell Signal 2011;23:1515-1527.
36. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R: Pik3ca mutations in patients with advanced cancers treated with pi3k/akt/mtor axis inhibitors. Mol Cancer Ther 2011;10:558-565.
37. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Basecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA: Roles of the raf/mek/ erk and pi3k/pten/akt/mtor pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011;3:192-222.
38. Zoncu R, Efeyan A, Sabatini DM: Mtor: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
39. Li C, Siragy HM: (pro)renin receptor regulates autophagy and apoptosis in podocytes exposed to high glucose. Am J Physiol Endocrinol Metab 2015;309:E302-310.
40. Zhu M, Li J, Wang K, Hao X, Ge R, Li Q: Isoquercitrin inhibits hydrogen peroxide-induced apoptosis of ea.Hy926 cells via the pi3k/akt/gsk3beta signaling pathway. Molecules 2016 21;21. pii: E356. doi: 10.3390/molecules21030356. DOI: 10.3390/molecules21030356.
41. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, He J: Report of incidence and mortality in china cancer registries, 2009. Chin J Cancer Res 2013;25:10-21.
42. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
43. Hirata K, Egawa S, Kimura Y, Nobuoka T, Oshima H, Katsuramaki T, Mizuguchi T, Furuhata T: Current status of surgery for pancreatic cancer. Dig Surg 2007;24:137-147.
44. Bae HJ, Jung KH, Eun JW, Shen Q, Kim HS, Park SJ, Shin WC, Yang HD, Park WS, Lee JY, Nam SW: Microrna-221 governs tumor suppressor hdac6 to potentiate malignant progression of liver cancer. J Hepatol 2015;63:408-419.
45. Nassirpour R, Mehta PP, Baxi SM, Yin MJ: Mir-221 promotes tumorigenesis in human triple negative breast cancer cells. Plos One 2013;8:e62170.
46. Panarelli NC, Chen YT, Zhou XK, Kitabayashi N, Yantiss RK: Microrna expression aids the preoperative diagnosis of pancreatic ductal adenocarcinoma. Pancreas 2012;41:685-690.
47. Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, Lin SC: Mir-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med 2011;40:560-566.
48. Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, Ma Q, Xiao C, Fan Q, Ma B: Microrna-221 induces cell survival and cisplatin resistance through pi3k/akt pathway in human osteosarcoma. Plos One 2013;8:e53906.
49. Li R, He JL, Chen XM, Long CL, Yang DH, Ding YB, Qi HB, Liu XQ: Mir-200a is involved in proliferation and apoptosis in the human endometrial adenocarcinoma cell line hec-1b by targeting the tumor suppressor pten. Mol Biol Rep 2014;41:1977-1984.
50. Worby CA, Dixon JE: Pten. Annu Rev Biochem 2014;83:641-669.